Evidence map›Paper›PMID 36085278›Full record

ArticleNature communications2022

Inhibition of the Niemann-Pick C1 protein is a conserved feature of multiple strains of pathogenic mycobacteria.

Yuzhe Weng, Dawn Shepherd, Yi Liu, Nitya Krishnan, Brian D Robertson, Nick Platt, Gerald Larrouy-Maumus, Frances M Platt

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Characterization of new mouse models of acute and chronicAntimicrobial agents and chemotherapy · 2025
    Article
  2. Molecular biology of the cell · 2025
    Article
  3. Sphingosine kills Mycobacteria and suppresses mycobacterial lung infections.Journal of molecular medicine (Berlin, Germany) · 2025
    Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuzhe Weng *Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.ORCID 0000-0002-1197-2513
Dawn Shepherd *Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.
Yi LiuMRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK.ORCID 0000-0001-6830-1254
Nitya KrishnanMRC Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, Flowers Building, London, SW7 2AZ, UK.
Brian D RobertsonMRC Centre for Molecular Bacteriology and Infection, Department of Infectious Disease, Imperial College London, Flowers Building, London, SW7 2AZ, UK.
Nick PlattDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK.
Gerald Larrouy-MaumusMRC Centre for Molecular Bacteriology and Infection, Department of Life Sciences, Faculty of Natural Sciences, Imperial College London, London, UK.
Frances M PlattDepartment of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK. frances.platt@pharm.ox.ac.uk.ORCID 0000-0001-7614-0403
Imperial College London · GBUniversity of Oxford · GB

Funding

Wellcome TrustWellcome Trust 202834/Z/16/Z
6 · The paper itself

Abstract

Mycobacterium tuberculosis (Mtb) survives and replicates within host macrophages (MΦ) and subverts multiple antimicrobial defense mechanisms. Previously, we reported that lipids shed by pathogenic mycobacteria inhibit NPC1, the lysosomal membrane protein deficient in the lysosomal storage disorder Niemann-Pick disease type C (NPC). Inhibition of NPC1 leads to a drop in lysosomal calcium levels, blocking phagosome-lysosome fusion leading to mycobacterial survival. We speculated that the production of specific cell wall lipid(s) that inhibit NPC1 could have been a critical step in the evolution of pathogenicity. We therefore investigated whether lipid extracts from clinical Mtb strains from multiple Mtb lineages, Mtb complex (MTBC) members and non-tubercular mycobacteria (NTM) inhibit the NPC pathway. We report that inhibition of the NPC pathway was present in all clinical isolates from Mtb lineages 1, 2, 3 and 4, Mycobacterium bovis and the NTM, Mycobacterium abscessus and Mycobacterium avium. However, lipid extract from Mycobacterium canettii, which is considered to resemble the common ancestor of the MTBC did not inhibit the NPC1 pathway. We conclude that the evolution of NPC1 inhibitory mycobacterial cell wall lipids evolved early and post divergence from Mycobacterium canettii-related mycobacteria and that this activity contributes significantly to the promotion of disease.

Indexed as

Mycobacterium bovisMycobacterium InfectionsHumansLipidsMycobacteriumNiemann-Pick C1 ProteinLipidsNiemann-Pick C1 Protein

Identifiers

PMID36085278
PMCPMC9463166
OpenAlexW4295067074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.